Objective: Persistent secondary hyperparathyroidism (SHPT) may occur because of residual cervicothoracic parathyroids in parathyroidectomy (PTX) patients with chronic kidney disease. We prospectively compared the predictive values of intraoperative plasma (1-84) parathyroid hormone (PTH) and intact PTH (iPTH) levels to improve the safety and efficacy of PTX.
Methods: We included 100 healthy controls, 162 stage 5 chronic kidney disease patients without SHPT, and 214 patients who underwent PTX because of SHPT. Plasma iPTH and (1-84) PTH levels were measured before incision (io-iPTH0 and io-[1-84]PTH0, respectively) and 10 minutes (io-iPTH10 and io-[1-84]PTH10, respectively) and 20 minutes (io-iPTH20 and io-[1-84]PTH20, respectively) after removing all parathyroids. The percentage reduction of iPTH and (1-84) PTH at 10 minutes (io-iPTH10% and io-[1-84]PTH10%, respectively) and 20 minutes (io-iPTH20%, and io-[1-84]PTH20%, respectively) was calculated. iPTH and (1-84) PTH were measured using second- and third-generation PTH assays, respectively.
Results: Compared with the controls and non-PTX patients, the PTX group had more obvious mineral metabolism disorders. There were 187 successful PTXs, 19 patients with persistent SHPT, and 8 patients lost to follow-up. The receiver operating characteristic curves revealed that io-(1-84)PTH10% >86.6% and io-(1-84)PTH20% >87.5% suggested successful PTX. The sensitivity of io-iPTH20% and io-(1-84)PTH20% were higher than those at the timepoint of 10 minutes. Moreover, the specificity and sensitivity of the (1-84) PTH reduction percentage were superior to that of iPTH.
Conclusion: Intraoperative reduction percentages of plasma (1-84) PTH levels are superior to iPTH for accurately predicting successful PTX, especially at 20 minutes after all cervicothoracic parathyroids had been resected.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eprac.2021.04.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Personalized parathyroid hormone therapy for hypoparathyroidism: Insights from pharmacokinetic-pharmacodynamic modelling.
Br J Clin Pharmacol
December 2024
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Article Synopsis
- The aim was to determine whether continuous or multiple daily doses of PTH would be more effective in reducing urinary calcium excretion and lowering the nephrolithiasis risk, using a pharmacokinetic-pharmacodynamic (PKPD) model.
- The results indicated that continuous PTH infusion significantly improved phosphate clearance, although its effect on calcium clearance was less pronounced, suggesting that further research on continuous administration is warranted.
Hemodialysis Patients May Benefit from Cholecalciferol Treatment Targeting High Level of 25(OH)D.
Medicina (Kaunas)
November 2024
Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, 80-210 Gdańsk, Poland.
Article Synopsis
- Vitamin D plays a role in Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), particularly affecting secondary hyperparathyroidism in hemodialysis (HD) patients, and while cholecalciferol is recommended for vitamin D deficiency, its effects on CKD-MBD are not entirely clear.
- An observational study involved 22 HD patients with vitamin D levels between 30-50 ng/mL receiving cholecalciferol to boost their levels above 75 ng/mL, comparing baseline biochemical markers with those at higher vitamin D levels.
- The study found that 73% of participants achieved the target vitamin D level in about 7.5 weeks with a total dose of 525,000
PTH immunoassay interference: differential diagnosis with normocalcemic primary hyperparathyroidism?
Arch Endocrinol Metab
November 2024
Universidade Federal de São Paulo Escola Paulista de Medicina Departamento de Endocrinologia e Metabolismo São PauloSP Brasil Departamento de Endocrinologia e Metabolismo, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil.
The main diagnostic dilemma in normocalcemic hyperparathyroidism is differentiating this condition from secondary hyperparathyroidism and other causes of elevated parathyroid hormone (PTH) levels in eucalcemic patients, including potential assay interferences. Despite the analytical sensitivity of immunoassays, they may lack adequate accuracy due to several analytical interferences, such as the presence of heterophilic antibodies. Immunoassays for PTH measurement use the immunometric "sandwich" technique, and only a few cases of interference with this assay have been reported to date.
View Article and Find Full Text PDFHypoparathyroidism: an update on new therapeutic approaches.
Endocrine
October 2024
Department of Pediatrics, IRCCS Ospedale San Raffaele, Milano, Italy.
Background: Hypoparathyroidism is a rare endocrine disease characterized by insufficient parathyroid hormone (PTH) secretion by the parathyroid glands, leading to hypocalcemia. In contrast to most hormone deficiencies for which hormone replacement is currently the mainstay of therapy, hypoparathyroidism has conventionally been treated with calcium supplements and active analogs of vitamin D. Although the advent of a replacement therapy with 1-34 and 1-84 PTH represented a major step in the therapeutic history of hypoparathyroidism, several new molecules and different management strategies have recently been developed.
View Article and Find Full Text PDFReceptor activity-modifying protein modulation of parathyroid hormone-1 receptor function and signaling.
Front Pharmacol
September 2024
Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.
Introduction: Receptor activity-modifying proteins (RAMPs) are known to modulate the pharmacology and function of several G-protein-coupled receptors (GPCRs), including the parathyroid hormone 1 receptor (PTH1R). However, the precise effects of different RAMPs on PTH1R signalling and trafficking remain poorly understood. This study investigated the impact of RAMP2 and RAMP3 on PTH1R function using a range of PTH and PTH-related protein (PTHrP)-derived ligands.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!